Pain management continues to face the dual hurdles of abuse of the most efficacious (opiod based) therapies and the difficulties of developing and commercialising new treatments. This challenging environment presents difficulties both for large pharmaceutical companies looking to bring new solutions to market and the mid size and smaller biotechs developing new approaches and seeking commercial partners. 

Reducing Pain for Patients and Dealmakers

Download Request